<DOC>
	<DOCNO>NCT00187889</DOCNO>
	<brief_summary>Some woman chest pain even without blockage one major blood vessel supply blood heart . In many woman microscopic ( small ) blood vessel heart function normally . This study seek determine treatment eplerenone , commercially available diuretic , improve function microscopic blood vessel , possibly , improve chest pain .</brief_summary>
	<brief_title>EWISE : Study Eplerenone Women With Chest Pain , Coronary Vascular Dysfunction Evidence Myocardial Ischemia</brief_title>
	<detailed_description>INDICATION : Coronary Vascular Dysfunction ( Endothelial Dysfunction and/or Microvascular angina ) . OBJECTIVES : To investigate effect aldosterone blockade ( eplerenone ) coronary vascular function . PATIENT POPULATION : Women meet National Heart , Lung Blood Institute-sponsored WISE ( Women Ischemia Syndrome Evaluation ) study criterion chest discomfort , coronary vascular dysfunction undergo evaluation myocardial ischemia absence significant coronary artery stenosis . STUDY DESIGN : A prospective , randomize , double blind placebo-controlled , comparative trial eplerenone , give presence renin-angiotensin blocker ( ACE-I ARB case ACE-I intolerance ) . TREATMENT : Eplerenone 25mg titrate 50mg tolerated per day versus placebo four month PRIMARY EFFICACY PARAMETER ( S ) : Epicardial coronary artery endothelial function Week 16 ( adjust baseline treatment group site treatment interaction variable ) compare eplerenone group placebo group . SECONDARY EFFICACY PARAMETERS : Microvascular coronary endothelial function Week 16 ( adjust baseline treatment group site treatment interaction variable ) compare eplerenone group placebo group . OTHER EFFICACY PARAMETERS : - Coronary flow reserve - Chest discomfort measure Seattle Angina Questionnaire - DASI SAFETY PARAMETERS : Blood pressure , pulse rate frequency occurrence adverse event . The latter include serum K Creatinine . STATISTICAL RATIONALE AND ANALYSIS : A statistical rationale number patient study provide . Interim analysis plan 10 patient complete treatment group . ANTICIPATED TOTAL NUMBER OF PATIENTS : 50 ( 25 per treatment group ) . ANTICIPATED NUMBER OF PATIENTS AT EACH SITE : Approximately 13 . PARTICIPATING SITES : University Florida ( Carl Pepine , MD ) , Emory University ( Arshed Quyyumi , MD ) , Rhode Island Hospital ( Barry Sharaf , MD ) , Mayo Clinic ( Amir Lerman , MD ) . There exist relationship first 3 site Mayo Clinic site familiar necessary protocol procedure anxious participate . The University Florida serve main contracting site .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Chest Pain</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Nonpregnant woman chest discomfort 21 75 year age diverse racial/ethnic group . Suspected ischemic heart disease ( IHD ) severe coronary stenosis ( &gt; 50 % diameter reduction ) coronary angiography use qualify WISE . Endothelial dysfunction , defined failure dilate intracoronary acetylcholine ( &lt; 5 % increase mean lumen diameter ) . If possible , patient take stable , maximally tolerate dose either angiotensinconverting enzyme inhibitor [ ACEI ] ( angiotensin II receptor blocker [ ARB ] ACEI intolerant ) Women breastfeed pregnant . Women childbearing potential may enrol must agree become pregnant course study must practice method birth control consider reliable investigator . If establish hormonal contraceptive 3 month , patient allow participate provided therapy remain constant throughout study . If patient becomes pregnant begin breastfeed study , must withdraw immediately . Acute ischemic syndrome define acute myocardial infarction [ MI ] ( enzyme electrocardiogram [ ECG ] criterion ) unstable angina within 1 month entry . Uncontrolled moderate hypertension : sit blood pressure &gt; 160/95mmHg measurement record least 2 occasion ( blood pressure control patient must first stabilize , preferably diuretic , remain dose regimen throughout participation study ) . Severe heart failure define New York Heart Association ( NYHA ) Class III IV treatment . Coronary revascularization either coronary artery bypass grafting ( CABG ) percutaneous transluminal coronary angioplasty ( PTCA ) stent placement . Conditions likely influence outcomes independent IHD : severe lung , renal ( creatinine &gt; 1.8 creatinine clearance [ CrCl ] â‰¤ 50ml/min ) hepatic disease ; surgically uncorrected significant congenital valvular heart disease ; diseases likely fatal require frequent hospitalization within next six month . Adherence retention reason : recent alcoholism drug abuse ; psychiatric illness include severe depression ; dementia ; active participation research trial WISE ; unwilling complete followup evaluation include repeat testing . Hypersensitivity medication use study Documented obstructive hypertrophic cardiomyopathy . Aortic stenosis ( valve area &lt; 1.5cm ) . Left ventricular ( LV ) dysfunction ( ejection fraction &lt; = 35 % ) . History significant cocaine amphetamine abuse . Serum potassium &gt; 5.0meq/l baseline Taking potent CYP3A4 inhibitor ( ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir ) Intolerance ACEI ARB medication Use potassium supplement potassium spar diuretic</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Microvascular Disease</keyword>
	<keyword>Women</keyword>
	<keyword>Ischemic Heart Disease</keyword>
	<keyword>WISE</keyword>
</DOC>